Since 1990, helping busy clinicians master the science and art of caring for people with HIV disease.

spacer move your mouse over me
spacer
spacer

The PRN Notebook

spacer
Featured Articles & VideosVisit The PRN Notebook
logo

Predicting Success and Failure on Long-acting Cabotegravir/RilpivirinePredicting Success and Failure on Long-acting Cabotegravir/Rilpivirine

Is long-acting cabotegravir/rilpivirine 100% effective? Not quite. Though relatively rare, there are measurable factors that, when present, are independent predictors of virologic failure in people on treatment with injectable, CAB/RPV LA for HIV disease. Dr. Kuritzkes, a long-time thought leader in HIV treatment success and failure, dives into the details.

logo

2022 Update on Immunization Recommendations for Individuals With and At-risk for HIV Disease2022 Update on Immunization Recommendations for Individuals With and At-risk for HIV Disease

Immunizations are our best bet for combatting preventable disease in all people, young and old. And in our patients with and at-risk for HIV infection, immunizations have never been more important than in the topsy-turvy world of infectious diseases we are living through! Dr. Jane Zucker returns with critical updates to current vaccine recommendations in adults and adolescents and Dr. Tristan McPherson will add updates on current monkeypox (MPX) prevention strategies.

logo

Highlights from the 24th International AIDS Conference: Montreal 2022Highlights from the 24th International AIDS Conference: Montreal 2022

This program presented by David Hardy is a review of highlights from AIDS 2022: the live 24th International AIDS Conference in Montreal, Canada, including clinically relevant advances in antiretroviral therapy and PrEP, emerging adverse effects, as well as new agents for HIV treatment and prevention.

logo

Monkeypox Epidemic Outside of Endemic Regions: Experience from the UK & EuropeMonkeypox Epidemic Outside of Endemic Regions: Experience from the UK & Europe

The last thing we need is another pandemic, but it looks like that is what is happening with Monkeypox (MPX), especially in men who have sex with men (MSM). This epidemic outside of endemic regions of Africa was first noted in England and other parts of Europe. Now that this infection is exploding in the United States, we have invited Sanjay Bhagani from the Royal Free in London to speak on his experiences dealing with MPX from the very beginning.

logo

Impact of COVID-19 on HIV and HCV Screening and Lessons Learned for 2022Impact of COVID-19 on HIV and HCV Screening and Lessons Learned for 2022

We all know how COVID-19 has upended health care since 2020 but how much has it affected HIV and HCV screening, diagnosis, and treatment? How can we get back on track in 2022? Don’t miss this thought-provoking presentation by Martin Hoenigl.

logo

PET Imaging Provides Novel Insights Into HIV/SIV and SARS-CoV-2 Disease ProgressionPET Imaging Provides Novel Insights Into HIV/SIV and SARS-CoV-2 Disease Progression

We have seen the dazzling and thought-provoking images from Tom Hope in the past and in this new presentation we will see further advances from macro- to micro-imaging that reveal progression of SIV and SARS-CoV-2 infection in non-human primate models. His recent research focuses on HIV-related mucosal immunology, HIV transmission and prevention science, as well as infection-related disease progression for COVID-19 and long COVID.

logo

Weight Gain and Obesity in People with HIVWeight Gain and Obesity in People with HIV

What is the current impact of antiretroviral therapy on weight gain?  And how do weight gain and adipose distribution effect clinical outcomes in people living with HIV?  Todd Brown provide a comprehensive review of the current evidence, as well as optimal approaches to weight gain prevention and treatment in PLWH.

logo

HIV Remission in a Woman of Mixed Race with AML and HIV: The New York PatientHIV Remission in a Woman of Mixed Race with AML and HIV: The New York Patient

First there was the Berlin patient, then the London patient, and now, we have the New York patient who is a mixed-race cisgender woman cured of HIV.  There are other important differences between this new cure including the use of cord blood in her stem cell transplant.  Don’t miss this important description of her case, as presented by Drs. Marshall Glesby and Deborah Persaud.

logo

Long COVID in People With and Without HIVLong COVID in People With and Without HIV

What are the post-acute sequelae of SARS-CoV-2 that define long COVID? Is it different in people living with HIV? This presentation by Keri Althoff will help you understand the phenotypes and possible mechanisms of long COVID. Dr. Althoff will also focus on the manifestations of long COVID in people living with HIV.

logo

Prostate Cancer in Cisgender Gay and Bisexual Men and Trans WomenProstate Cancer in Cisgender Gay and Bisexual Men and Trans Women

Is the experience of diagnosis and treatment of prostate cancer different in gay and bisexual men than it is in straight men?  Dr. Channa Amarasekera, the director of the first Gay and Bisexual Men’s Urology Program in the country, thinks so. In this important presentation, you will learn about his efforts to improve the urologic care experience, outcomes and quality of life for cisgender men who identify as gay or bisexual.  You will also appreciate how HIV infection influences prostate cancer screening and treatment.

logo

Preventing Anal Cancer: Results from the ANCHOR StudyPreventing Anal Cancer: Results from the ANCHOR Study

We have known for a long time that the incidence of anal cancer associated with HPV infection is higher amongst people living with HIV. But now, with the results of the ANCHOR study, we know that identification of anal high-grade squamous intraepithelial lesions (HSIL) through high resolution anoscopy (HRA) followed by destruction of these pre-cancerous lesions has been proven to prevent progression to anal cancer. In this presentation, Joel Palefsky returns to PRN to share the exciting results of the ANCHOR study and its implications for a new standard of care in people living with HIV.

logo

CROI 2022: Updates on HIV Treatment & Prevention and SARS-COV-2CROI 2022: Updates on HIV Treatment & Prevention and SARS-COV-2

Every year the Conference on Retrovirology and Opportunistic Infections (CROI) is packed with important new information in HIV medicine and again this year includes COVID-19 as well. Don’t miss this engaging review by Trip Gulick on CROI 2022 highlights in HIV cure, new drugs, treatment strategies and prevention, as well as the latest on SARS CoV-2 and COVID-19.

logo

Rapid Initiation of HIV Antiretroviral Treatment (RIA)Rapid Initiation of HIV Antiretroviral Treatment (RIA)

Early diagnosis of HIV disease and linkage to medical care have finally come of age.  But how can we speed the accurate diagnosis and initiation of a safe antiretroviral regimen and stop the chain of further transmission? What barriers have we overcome, and which barrier remain?  Don’t miss this important talk by Tony Urbina on the current state-of-the-art in rapid initiation of antiretroviral treatment (RIA) for HIV infection.

logo

Healthy Aging with HIV in the Context of COVID-19Healthy Aging with HIV in the Context of COVID-19

When you really think about it, healthy aging is the ultimate goal of HIV management.  In the context of polypharmacy so often seen in older people, and in the midst of the the COVID-19 pandemic, Giovanni Guaraldi will help you understand the principles of HIV geriatric medicine, assess biological age with frailty, appreciate different models of HIV care in older adults, and maintain optimal antiretroviral therapy while deprescribing polypharmacy.

logo

HIV Testing: Time for a Change, and the Reasons WhyHIV Testing: Time for a Change, and the Reasons Why

Pre-exposure prophylaxis, especially long-acting PrEP, affects the laboratory diagnosis of HIV.  And the current diagnostic algorithm needs some updating anyway. In this presentation, Bernie Branson discusses the aging HIV diagnostic algorithm and ways to improve it, the difference between HIV RNA for diagnosis vs. monitoring, and which tests are necessary before initiating ART.

logo

Updates on COVID-19 Treatment and HIV/COVID-19 CoinfectionUpdates on COVID-19 Treatment and HIV/COVID-19 Coinfection

Evidence-based treatment options for COVID-19 in non-hospitalized patients are expanding. In this presentation Raj Gandhi will discuss the most current approaches to treating non-hospitalized patients with COVID-19, as well as important considerations for hospitalized patients.  Additionally, Dr. Gandhi will summarize our current understanding of COVID-19 in people living with HIV.

logo

Update on Genetic Prediction of Future Cardiovascular DiseaseUpdate on Genetic Prediction of Future Cardiovascular Disease

In addition to genetic testing that we can order for clinical purposes, our patients are increasingly turning to direct-to-consumer (DTC) genetic testing on their own, to explore their ancestry. But if one of these DTC tests also shows increased risk for cardiovascular disease (CVD), then your patient’s next likely stop will be with you to discuss the relative importance of this discovery. Are you ready for this? Dr. Wendy Post, an expert on CVD and HIV/AIDS, is also immersed in the study of the genetics of CVD. In this presentation, Dr. Post will review what is currently known about the genetic risks for CVD, and how lifestyle modification can influence the genetic risk for CVD. She will also review the strengths and limitations of polygenic risk scores for CVD and commercially available genetic testing.

logo

EACS 2021: Highlights from the European AIDS ConferenceEACS 2021: Highlights from the European AIDS Conference

2021 marks the 18th year of the European AIDS Conference, this year in London.  Juergen Rockstroh, a past president of EACS,  provides compelling conference updates, focussing on epidemiology, diagnostics, treatments, aging and the impact of COVID-19 on people living with HIV in Europe.

logo

Organ Transplantation for People Living with HIV/AIDS: Advances and ChallengesOrgan Transplantation for People Living with HIV/AIDS: Advances and Challenges

We all know that some of our patients living with HIV may one day need a heart, liver or kidney transplant—but do all of our HIV positive patients know that they can be organ donors? In her comprehensive and up-to-date presentation, Sapna Mehta reviews the current studies evaluating outcomes of HIV positive organ use for HIV positive recipients.  It’s time to spread the word.

logo

HIV/HCV CoinfectionHIV/HCV Coinfection

How does HIV coinfection affect the epidemiology, progression and treatment of hepatitis C (HCV)?  In this presentation, Brianna Norton will bring you up-to-date on the natural progression of liver disease in HIV/HCV coinfected individuals and discuss the differences in HCV epidemiology among HIV/HCV coinfected versus HCV monoinfected individuals. Dr. Norton will also discuss drug-drug interactions between HIV antiretrovirals and HCV directly-acting-antivirals.

logo

COVID-19 Vaccine Progress and PredicamentsCOVID-19 Vaccine Progress and Predicaments

Up-to-date knowledge of COVID-19 vaccines, newer vaccine options under development, and the evidence for and against booster shots have never been more important during this pandemic. Kristen Marks will discuss these issues as well as adverse events secondary to COVID-19 vaccines, and common vaccine management questions.

logo

Highlights from the Virtual IAS Conference on HIV Science 2021Highlights from the Virtual IAS Conference on HIV Science 2021

This program presented by David Hardy is a review of highlights from the Virtual IAS Conference on HIV Science 2021, including clinically relevant advances in antiretroviral therapy, metabolic effects, as well as investigational agents for HIV treatment and prevention.

logo

Advances in COVID-19 ManagementAdvances in COVID-19 Management

What clinicians and researchers have learned over these past 18 months during the COVID-19 pandemic is of critical importance to us now and may help us change outcomes for this as well as future pandemics.  Jügen Rockstroh’s thoughtful presentation will provide an update on COVID-19 epidemiology, diagnostics, treatments and vaccines from a European perspective.

logo

Inflammation, Morbidity and Mortality in Treated HIV: Roles of Asymptomatic CMV and Sex DifferencesInflammation, Morbidity and Mortality in Treated HIV: Roles of Asymptomatic CMV and Sex Differences

Chronic inflammation caused by herpesviruses (especially CMV) and by sex differences, leads to end-organ morbidities in HIV disease despite optimal treatment of HIV. In this presentation, Peter Hunt explores the causes and consequences of persistent immune activation in treated HIV infection, including its impact on age-related morbidity and mortality as well as HIV persistence.

logo

Liver Disease in the Face of COVID-19Liver Disease in the Face of COVID-19

Does COVID-19 infection contribute to liver disease? And does pre-existing liver disease affect the course of COVID-19 outcomes?  In this presentation, Elizabeth Verna addresses these important questions and also explains how the COVID-19 pandemic has impacted the care of patients with chronic liver disease including the initiatives regarding viral hepatitis elimination.

logo

Got anything for the Cough? Treatments for Early COVID-19Got anything for the Cough? Treatments for Early COVID-19

Despite the vaccine roll-out, new cases of COVID-19 persist; hence we still need tounderstand and optimize the treatments available to us, as well as those in development.  In this comprehensive presentation,  Davey Smith discusses current treatments as well as antiviral drugs in development for COVID-19.

logo

HIV-1 bNAbs: Looking AheadHIV-1 bNAbs: Looking Ahead

Marina Caskey provides a comprehensive update of broadly neutralizing antibodies (bNAbs) in the treatment and prevention of HIV.  Learn the latest on outcomes from recent engineered HIV bNAbs clinical trials, prevention efficacy studies, as well as new HIV bNAb delivery systems entering clinical evaluation.

logo

R4P 2021: Updates on the HIV Pre-Exposure Prophylaxis PipelineR4P 2021: Updates on the HIV Pre-Exposure Prophylaxis Pipeline

Every two years, HIV Research for Prevention (R4P) meets internationally and focuses solely on prevention modalities, technologies, and strategies.  In this thought-provoking presentation, Craig Hendrix reviews the highlights of HIV R4P, including long-acting PrEP, on-demand PrEP, and multipurpose prevention technologies

logo

HIV and COVID-19 in New York City: a Population-Level AnalysisHIV and COVID-19 in New York City: a Population-Level Analysis

We all worry about co-infections in our patients living with HIV/AIDS and their potential outcomes.  This is especially true in the COVID-19 pandemic. In this presentation, Dr. Sarah Braunstein, from the New York City Department of Health and Mental Hygiene, will discuss the intersection of HIV and COVID-19 in New York City and the growing evidence for higher risk of adverse COVID-19-related outcomes among people with HIV.

logo

State of the LA-ART: New Drug Delivery Technologies in HIV Treatment and PreventionState of the LA-ART: New Drug Delivery Technologies in HIV Treatment and Prevention

Long-acting antiretroviral formulations for HIV treatment and prevention - if nobody has asked you about why they are important and how they work, don’t miss this program, which will help you prepare.  Nanoformulations, erodable and non-erodable implant formulations, and other mechanisms for making drugs work longer are on the way, and Charles Flexner will discuss all of them in this engaging program.

logo

CROI 2021: Updates on HIV Treatment & Prevention and SARS-COV-2CROI 2021: Updates on HIV Treatment & Prevention and SARS-COV-2

Every year the Conference on Retrovirology and Opportunistic Infections (CROI) is packed with important new information in HIV medicine and this year including COVID-19 as well. Don’t miss this engaging review by Trip Gulick on CROI 2021 highlights in HIV cure, new drugs, treatment strategies, and prevention, as well as the latest on SARS CoV-2 and COVID-19.

logo

Fighting a Moving Target: SARS-CoV-2 Evolution and Viral Escape in COVID-19Fighting a Moving Target: SARS-CoV-2 Evolution and Viral Escape in COVID-19

From our experience with HIV, we all appreciate the impactof viral mutations.  In this PRN presentation, Jonathan Li discusses the evolution, viral escape, persistence, reinfection and novel strains of Sars-CoV-2 and how they are affecting the current COVID-19 pandemic.

logo

Addressing Behavioral Health Needs During the COVID-19 Pandemic: Patients with HIV and the Health Care TeamAddressing Behavioral Health Needs During the COVID-19 Pandemic: Patients with HIV and the Health Care Team

The Covid-19 pandemic has caused much distress – not just for our patients, but for our fellow healthcare providers as well.  But how can we differentiate mental distress from mental disorder? In this presentation, Dr. Francine Cournos will share findings from peer-reviewed literature pertaining to the behavioral health needs of patients with HIV and their health care providers alike.  She will also share simple behavioral health strategies, including the World Health Organization Pyramid of Mental Health Services to the COVID-19 pandemic.

logo

Prevention of New Pediatric HIV Infections: A Work in ProgressPrevention of New Pediatric HIV Infections: A Work in Progress

What progress has been made world-wide in the prevention of new pediatric HIV infections?  How has the COVID-19 pandemic impacted HIV services for pregnant women and infants?  In this presentation by Elaine Abrams, we will gain insight into these critical questions along with an understanding of optimal antiviral regimens for use during pregnancy and breastfeeding, as well as gaps along the cascade of care for prevention of vertical HIV transmission.

logo

Controversies in Testosterone Treatment 2020 in Cisgender and Transgender MenControversies in Testosterone Treatment 2020 in Cisgender and Transgender Men

Testosterone is prescribed frequently for hypogonadism in cisgender men living with HIV, aging cisgender men, and for gender-affirming therapy in transgender men.  But do we fully understand the benefits?  And what do we really know about the risks?  This presentation by Todd Brown will bring you up to date on the outcomes from pertinent studies including the Testosterone Trials (TTrials) in older cisgender men and what is presently known about the potential risks in transgender men.

logo

Progress Towards Developing an Effective HIV CureProgress Towards Developing an Effective HIV Cure

The chronic management of HIV disease has advanced so far already, do even need a cure? Join us for this exciting presentation by Steve Deeks addressing the needs for a broadly scalable cure for HIV, as well as research approaches that may help us achieve this ever-elusive yet long-sought goal.

logo

Atherosclerotic Cardiovascular Disease in HIV: Special Focus on Transgender and Cisgender WomenAtherosclerotic Cardiovascular Disease in HIV: Special Focus on Transgender and Cisgender Women

We all know that our patients living with HIV are at higher risk for atherosclerotic cardiovascular disease. But data on women has been lacking. In this presentation by Mabel Toribio, you will learn to describe mechanisms of heightened atherosclerotic cardiovascular disease among people living with HIV, along with prevention and treatment strategies. Dr. Toribio will be presenting her most current research, which includes under-represented populations – in particular, transgender and cisgender women.

logo

Leveraging Imaging Approaches to Define the Dynamics of SIV/HIV During & After ART & Adapting this Approach to Study SARS-CoV-2Leveraging Imaging Approaches to Define the Dynamics of SIV/HIV During & After ART & Adapting this Approac...

This captivating lecture by Tom Hope shows us how imaging approaches he has developed to study HIV, rebound reservoirs and latent cells after discontinuation of ART in non-human primates, can provide insight to HIV Cure research.  And these same imaging approaches developed to study HIV have been adapted by Dr. Hope to study COVID-19, leading to a clearer understanding of pathogenesis and intervention for this new pandemic.

logo

HIV Prevention Outreach in the 2020s: Grindr™, Gonorrhea, and HIV PrEPHIV Prevention Outreach in the 2020s: Grindr™, Gonorrhea, and HIV PrEP

Do Grindr™  users take more risks? Are Grindr™ users more likely to serosort? Dr. Martin Hoenigl will answer these questions. He will also cover novel ways to use geosocial mobile apps to better reach marginalized populations at risk for HIV/STIs and to promote testing and PrEP use.

logo

HIV Treatment in an Era of Polypharmacy: The Current and Future Challenges with Drug InteractionsHIV Treatment in an Era of Polypharmacy: The Current and Future Challenges with Drug Interactions

Are drug interactions still an HIV treatment issue in 2019? You bet they are, but how can we differentiate ARVs in terms of their mechanisms of action and interaction potential? And what commonly co-administered drugs, such as statins, psychotropics, proton pump inhibitors, steroids, and gender affirming hormones do we need to be on high-alert for? All this, plus interactions with recreational drugs, especially those used in chem-sex, are discussed. Don’t miss this important presentation by David Back, internationally recognized for his groundbreaking work in online interactive drug-drug interaction awareness. Your patients will thank you.

logo

Easing the Transition of HIV-Infected Adolescents to Adult CareEasing the Transition of HIV-Infected Adolescents to Adult Care

The expanding epidemic of HIV in young people, and their eventual move to the adult setting, poses many challenges to the quality and continuity of their medical care. In this program Joe Cervia targets the special needs and models of care that may ease the transitional challenges.

logo

The Berlin Patient: Eradication of HIV with CCR5 Deficient Hematopoietic Stem CellsThe Berlin Patient: Eradication of HIV with CCR5 Deficient Hematopoietic Stem Cells

This lecture was originally posted in 2012 but due to its ongoing relevance we are highlighting it again on our home page. CME credit is no longer available for this archived presentation. Almost everybody has heard of the "Berlin Patient," but how many of us have had an opportunity to meet and listen to his doctor from Berlin? In this video you will hear Gero Hütter tell about his rationale for performing a bone marrow transplant with CCR5 deficient hematopoietic stem cells, the long term outcomes for his patient, further research to understand if he has been "cured," and attempts to repeat this unique success.

The PRN Notebook

image

TRANSMISSION

Transmission, Diagnosis and the HIV Epidemic

View Article List

image

PROGRESSION

Pathogenesis and Progression of HIV Disease.

View Article List

image

MANAGEMENT

Treatment, Resistance and Management of HIV/AIDS

View Article List

image

COMPLICATIONS

Complications and Comorbidities

View Article List

image

COINFECTIONS

Coinfections and Opportunistic Infections

View Article List

Visit The PRN Notebook
spacer

Provider Resources

spacer

CME/MOC

spacer

Members Only

spacer

Provider Resources

CME/MOC

PRN is pleased to offer this new CME/MOC opportunity designed for physicians, nurse practitioners and physician assistants caring for patients with or at risk for HIV disease and its many complications. Based on content from The PRN Notebook, credit for each course will be available for a limited period of time noted on each activity.

View CME/MOC

Members Only

Full PRN membership is now open to clinicians nationwide.

  • Monthly Meeting Announcements and Pre-registration
  • CME/MOC for Meeting Attendees
  • Special Events

CLICK HERE TO JOIN OR RETURN

This website is partially funded by educational grants from:

Gilead Sciences Janssen Therapeutics Merck & Co ViiV Healthcare